Schering-plough elocon ointment

Consult your doctor for further information. This medicine should not be used during breastfeeding unless considered essential by your doctor. If it is prescribed by your doctor it should not be used on large areas of skin, underneath airtight dressings or for prolonged periods of time.

If it is applied to the breasts it should be washed off carefully before breastfeeding and then reapplied afterwards. Possible side effects of Elocon Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.

Skin irritation, eg itching, burning, tingling, stinging on application. Contents of the pack and other information What Elocon contains The active substance is mometasone furoate 0. What Elocon looks like and contents of the pack Elocon cream is available in a white, sealed aluminum collapsible tube with white plastic screw-cap which has a device to break the seal on the tube.

Elocon comes in a tube of 30grams. Schering Plough Labo N. Procured from within the EU and repackaged by the Product Licence holder: You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others.

It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. The name of your medicine is Mometasone furoate 0. The criteria for suppression were: Follow-up testing 2 to 4 weeks after trial completion, available for 5 of the subjects, demonstrated suppressed HPA axis function in 1 subject, using these same criteria.

Long-term use of topical corticosteroids has not been studied in this population [see Clinical Pharmacology Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids.

Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids.

Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.

However, greater sensitivity of some older individuals cannot be ruled out. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity. Mometasone furoate is a white to off-white powder practically insoluble in water, slightly soluble in octanol, and moderately soluble in ethyl alcohol.

The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.

It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The results showed that the drug caused a slight lowering of adrenal corticosteroid secretion [see Warnings and Precautions 5.

Ninety-seven pediatric subjects ages 6 to 23 months with atopic dermatitis were enrolled in an open-label HPA axis safety study. Follow-up testing 2 to 4 weeks after stopping treatment, available for 5 of the subjects, demonstrated suppressed HPA axis function in one subject, using these same criteria [see Use in Specific Populations 8.

Studies in humans indicate that approximately 0. Long-term carcinogenicity studies of mometasone furoate were conducted by the inhalation route in rats and mice. Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay.

Tags: viagra holland kaufen rezeptfrei obsessive compulsive personality disorder zoloft alli orlistat precio argentina phentermine buy without rx viagra order and price mix augmentin suspension pediatrica precio